Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lerong Li

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
JAMA Oncology|September 30, 2018
Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical TrialErminia Massarelli, William William, Faye Johnson, et al.
Oncotarget|November 2, 2017
Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapiesRobert J Cardnell, Lerong Li, Triparna Sen, et al.
Oncotarget|February 18, 2017
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancerC Allison Stewart, Pan Tong, Robert J Cardnell, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 25, 2019
Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinomaRoberto Ruiz-Cordero, Priya Rao, Lerong Li, et al.
Science Translational Medicine|November 10, 2017
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockersMonique B Nilsson, Huiying Sun, Lixia Diao, et al.
Cell Metabolism|April 10, 2018
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell TherapyTina Cascone, Jodi A McKenzie, Rina M Mbofung, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
JAMA Oncology|September 30, 2018
Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical TrialErminia Massarelli, William William, Faye Johnson, et al.
Oncotarget|November 2, 2017
Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapiesRobert J Cardnell, Lerong Li, Triparna Sen, et al.
Oncotarget|February 18, 2017
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancerC Allison Stewart, Pan Tong, Robert J Cardnell, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 25, 2019
Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinomaRoberto Ruiz-Cordero, Priya Rao, Lerong Li, et al.
Science Translational Medicine|November 10, 2017
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockersMonique B Nilsson, Huiying Sun, Lixia Diao, et al.
Cell Metabolism|April 10, 2018
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell TherapyTina Cascone, Jodi A McKenzie, Rina M Mbofung, et al.
Pageof 3